首页> 外文期刊>mSphere >nBioChip, a Lab-on-a-Chip Platform of Mono- and Polymicrobial Biofilms for High-Throughput Downstream Applications
【24h】

nBioChip, a Lab-on-a-Chip Platform of Mono- and Polymicrobial Biofilms for High-Throughput Downstream Applications

机译:nBioChip,用于高通量下游应用的单微生物和生物微生物膜的芯片实验室平台

获取原文
       

摘要

Current in vitro techniques for the culture of microorganisms, and particularly of delicate microbial biofilms, are still mostly limited to low-density plates and manual labor and are not amenable to automation and true high-throughput (HT) applications. We have developed a novel fully automated platform for the formation of mono- and polymicrobial biofilms of Staphylococcus aureus , Pseudomonas aeruginosa , and Candida albicans at the nanoscale level. The nBio Chip is robotically printed, robustly handled, and scanned using a standard microarray reader. Using this technique, hundreds to thousands of identical nanobiofilms encapsulated in hydrogel spots were cultured on microscope slides. The spots can withstand the washing steps involved in screening assays. The miniaturized biofilms demonstrated characteristics similar to those displayed by conventionally formed macroscopic biofilms, including (i) three-dimensional architectural features, (ii) synthesis of exopolymeric matrix material, and (iii) elevated resistance to antibiotic treatment. On the basis of our results, the nBio Chip can generate reliable high-throughput antimicrobial susceptibility testing (HT-AST) in 12 to 18?h. The chip serves as a proof-of-concept universal platform for high-throughput drug screening and other downstream applications and furthers understanding of microbial interactions in mixed-species communities at the nanoscale level. IMPORTANCE With an estimated 80% of infections being associated with a biofilm mode of growth and the ensuing recalcitrance of these biofilms with respect to conventional antibiotic treatment leading to high mortality rates, there is a dire and unmet need for the development of novel approaches to prevent, treat, and control these infections. Both bacteria and fungi are capable of forming biofilms that are inherently fragile and often polymicrobial in nature, which further complicates treatment. In this work, we showcase a nanobiofilm chip as a convenient platform for culturing several hundreds of mono- or polymicrobial biofilms and for susceptibility testing. This platform enables true ultra-high-throughput screening for antimicrobial drug discovery or diagnostics or for addressing fundamental issues in microbiology.
机译:当前用于培养微生物特别是脆弱的微生物生物膜的体外技术仍主要限于低密度板和体力劳动,并且不适于自动化和真正的高通量(HT)应用。我们已经开发了一种新型的全自动平台,用于在纳米水平上形成金黄色葡萄球菌,铜绿假单胞菌和白色念珠菌的单微生物和生物微生物膜。 nBio芯片通过标准微阵列读取器进行自动打印,坚固处理和扫描。使用这种技术,在显微镜载玻片上培养了成百上千个封装在水凝胶斑点中的相同纳米生物膜。这些斑点可以承受筛选试验中涉及的洗涤步骤。微型化的生物膜表现出与常规形成的宏观生物膜类似的特征,包括(i)三维结构特征,(ii)外聚合基质材料的合成和(iii)对抗生素治疗的抗性增强。根据我们的结果,nBio芯片可在12至18?h内产生可靠的高通量抗菌药敏测试(HT-AST)。该芯片可作为概念验证的通用平台,用于高通量药物筛选和其他下游应用,并在纳米级别上进一步了解混合物种社区中的微生物相互作用。重要性由于估计有80%的感染与生物膜的生长方式有关,并且这些生物膜对常规抗生素治疗的顽固性导致高死亡率,因此迫切需要解决新的预防方法,治疗和控制这些感染。细菌和真菌都能够形成生物膜,这种生物膜本质上是脆弱的,并且通常具有多种微生物,这使治疗更加复杂。在这项工作中,我们展示了纳米生物膜芯片,作为培养数百种单微生物或多生物膜以及药敏试验的便捷平台。该平台可进行真正的超高通量筛选,用于发现或诊断抗菌药物或解决微生物学中的基本问题。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号